B-Myb expression, and not IFN-I unresponsiveness, is one factor promoting arenavirus replication a: mRNA expression levels of Ifnar1 and Ifnar2 for the cancer types renal cell cancer (RCC; n=534), hepatocellular cancer (HCC; n=373), colorectal cancer (CRC; n=382), head and neck squamous cell cancer (HNSCC; n=522) and skin cutaneous melanomas (SKCM; n=471). Downloaded from the TCGA database by use of cBioPortal (www.cbioportal.org). Data are shown as mean and minimum-maximum whiskers. b: qRT-PCR of human Ifnar1 and Ifnar2 mRNA expression in Sw480, HeLa, HepG2, FADU cells and controls (murine mRNA, n=5/group). c: Number of viral plaques in Sw480 cell layer (n=6/group, left panel) and HeLa cell layer (n=5/group, right panel), which were treated with different concentrations of human IFN4, murine IFN4 or murine IFN2 and infected with VSV (MOI 0.01) 24 hours earlier. d: qRT-PCR of murine Ifnar1 mRNA in MOPC cells, MC38 cells, B16F10 cells, LoxP-Tag tumors, MT/ret cells and control (human mRNA, n=5/group). e&f: Immunofluorescence of phospho-B-Myb (e, n=3/group) and qRT-PCR of B-Myb (=Mybl2) mRNA (f, n = 9-10/group) in MOPC, MC38 and LoxP-Tag tumors compared to the correlating healthy tissue (oropharyngeal epithelia, colon and liver). Scale bar, 200µm. g: qRT-PCR of viral host factors in MOPC tumors (n=5) and pharynx tissue (n=5). h: Infectious LCMV particles in supernatant of MCF7 cells, which were treated with control siRNA or two separate B-Myb siRNAs and then 24 hours later infected with LCMV (MOI 1) analyzed 24 hours after infection (n = 6/group). Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non significant; *p < 0.05; **p < 0.01; ***p < 0.001. 4 PFU LCMV peritumorally on day 0. Depletion was performed by i.p. injection of either (a) αLy6C+G (clone RB6-8C5) 200µg or (b and c) αly6G (clone 1A8) 500µg starting on d-2 and repeated on d2 and d7. a&b: Representative dot blots of peripheral vein blood collected on d4 and stained for monocyte and granulocyte cell markers after preselection of CD11b positive cells. c: Tumor diameter in C57BL/6 mice injected with or without αLy6G (1A8) antibody (n=3-4/group). Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non-significant. qRT-PCR from tumors of MOPC-tumor bearing WT mice (day -3) treated with or without 2x10 4 PFU LCMV peritumorally (day 0), analyzed on day 6 (n= 3/group). b&c: Immunofluorescence (b, n= 3/group, CD31, red; DAPI, blue) and quantification of microvessel density (MVD) and vessel-vessel distances (c, n = 3/group) from MOPC-tumor bearing C57BL/6 mice (day -3) which were treated with or without 2x10 4 PFU LCMV peritumorally (day 0) measured on day 6. d: Immunohistochemistry (day 6) and quantification (day 9) of hypoxic areas from tumors of MOPC-tumor bearing C57BL/6 mice (day -3) treated with or without 2x10 4 PFU LCMV peritumorally on day 0 (n= 3 mice/group). e: Immunofluorescence of tumors from MOPC-tumor bearing C57BL/6 (day -3) treated with or without 2x10 4 PFU LCMV peritumorally on day 0 (n= 3/group, Ki-67 or cleaved caspase 3, red; DAPI, blue). Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non-significant; *p < 0.05 ; **p < 0.01; ***p < 0.001; Scale bar = 200µm. Supplementary Table 2 
